MedPath

A clinical study of a tumor-selective oncolytic adenovirus (Telomelysin) in combination with ionizing radiation for head and neck and thoracic malignant tumors

Phase 1
Conditions
Head and neck cancers, esophageal cancers, non-small cell lung cancers
Registration Number
JPRN-UMIN000010158
Lead Sponsor
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
12
Inclusion Criteria

Not provided

Exclusion Criteria

-Patient who has uncontrolled infectious disease and/or severe disease. -Patient who received chemotherapy, laser irradiation or stent placement within 3 weeks (or used nitrosourea or mitomycin C within 6 weeks). -Patient who receives non-local adrenocortical steroid therapy. -Patient who participated in clinical study of other unapproved drug within 4 weeks. -Patient who has or had (has less than 2 years after diagnosis of) other malignant tumors except for head and neck and thoracic malignant tumors. -Patient who cannot be kept or followed in this study due to mental, familial, social, geographical reasons. -Patient who has past history of autogenous or allogenic organ and tissue transplantations. -Patient who has positive result in serological test for HIV1, HIV2, HBV and HCV. -Patient who are considered inadequate by investigator.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath